| Business

Become a contributor

Bookmark Econotimes

| Business

Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support

Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube

Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions

L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown

SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round

Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support

Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration

Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power

Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force

Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics

Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies

Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy

Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts

Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades

Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro

Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026

ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China

©Econometrics LLC . All Rights Reserved.

Vical to Provide Company Update at BIO Investor Forum Conference

Friday, October 13, 2017 8:05 PM UTC

SAN DIEGO, Oct. 13, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at 11:30 a.m. PT on Wednesday, October 18, at the BIO Investor Forum Conference (San Francisco – October 17-18). A webcast of the company’s presentation will be available live through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.

About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.

Contact:
Tony Ramos
(858) 646-1127
Website: www.vical.com

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Market Data

Pentagon Awards $328.5 Million Lockheed Martin Contract to Support Taiwan Air Force Amid Rising Tensions

FxWirePro: USD/CAD trends higher, but faces potential pitfalls

FxWirePro: GBP/NZD sustains gains as uptrend remains strong

FxWirePro: EUR/NZD steadies above 2.0400, retains bid tone

China Imposes 55% Tariff on Beef Imports Above Quota to Protect Domestic Industry

FxWirePro: USD/ZAR remains weak, eyes 23.6%fib support

GBPJPY Coiled in Tight Range: Bullish Bias Holds Above 210 – Buy Dips Targeting 212 Breakout

Trump Administration Lifts Sanctions on Three Intellexa-Linked Executives

U.S. Intelligence Disputes Russia’s Claim of Ukrainian Drone Attack on Putin

EconoTimes

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

Vical to Provide Company Update at BIO Investor Forum Conference

Editor's Picks

Welcome to EconoTimes